Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation
ConclusionApixaban enhances endogenous fibrinolysis, with maximal effect in those with impaired fibrinolysis pre-treatment. Apixaban-treated patients exhibit more favourable fibrinolysis profiles than those taking warfarin or aspirin. Whether apixaban may confer additional thrombotic risk reduction in NVAF patients with impaired fibrinolysis, compared to warfarin, merits further study.
Source: Europace - Category: Cardiology Source Type: research
More News: Aspirin | Atrial Fibrillation | Cardiology | Coumadin | Ischemic Stroke | Stroke | Study | Thrombosis | Warfarin